Trabectedin has been shown to have particular effect in translocation-associated sarcomas such as myxoid LPS, where preclinical research has shown that trabectedin can reverse the transcriptional reprogramming orchestrated by the pathognomonic FUS-CHOP fusion gene [36]. Here, DDIT3 is linked to sarcoma.